Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 14, 2024
Reporting Period Covered: Three and six months ended June 30, 2024
Context: This filing serves to announce the issuance of a press release regarding the Company's financial results for the periods ended June 30, 2024. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior comparable periods. It only confirms that results for the three and six months ended June 30, 2024, have been issued.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing contains forward-looking statements regarding future financial performance, events, and trends. These are identified by terms such as "may," "expect," "anticipate," and "believe."
- Risks and Uncertainties: The Company notes that actual results may differ materially from projections due to known and unknown risks, many of which are outside the Company's control.
- Reference for Details: Detailed risk factors and management commentary are referenced in the Company's most recent Form 10-K and Form 10-Q filings, as well as the press release in Exhibit 99.1.
- Update Obligation: The Company undertakes no obligation to publicly update or revise forward-looking statements after the date of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 15, 2024) for specific revenue, net loss, and cash position figures.
- Verify the Company's cash runway and liquidity status as detailed in the full press release.
- Examine the "Risk Factors" section in the most recent Form 10-K or 10-Q for specific operational and financial risks.
- Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.